Physician profile
John Wheeler
NPI 1518931146
$4,900.81
in general payments reported to CMS, 2019-2025
30 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.58 · 2020: $70.38 · 2022: $147 · 2023: $727 · 2024: $1,746 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,620.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.37 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $590.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $480.68 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $351.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $343.98 | 2023-2025 | |
| Lilly USA, LLC | $227.67 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $222.79 | 2023-2025 | Trelegy Ellipta, Arexvy, Anoro Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.49 | 2023-2025 | Jardiance, Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $134.83 | 2024-2025 | |
| Amgen INC. | $132.96 | 2024-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $126.66 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $117.11 | 2023-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $99.51 | 2019-2025 | Trintellix |
| Viiv Healthcare Company | $86.60 | 2024-2025 | Apretude |
| Inspire Medical Systems, INC. | $76.62 | 2025 | Inspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $76.30 | 2025 | Recorlev, Keveyis |
| Exact Sciences Corporation | $51.72 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $50.60 | 2019-2024 | Veozah |
| Biogen, INC. | $45.23 | 2025 | Skyclarys, Zurzuvae |
| Lundbeck LLC | $39.17 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $36.45 | 2023 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $31.90 | 2024 | Evkeeza |
| Antares Pharma, INC. | $30.43 | 2025 | Xyosted |
| Genentech USA, INC. | $23.13 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.95 | 2025 | Caplyta |
| Ardelyx, INC. | $21.05 | 2024 | Ibsrela |
| Tandem Diabetes Care, INC. | $18.23 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ironshore Pharmaceuticals INC. | $15.81 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.37 | 2024 | Camzyos |
| Currax Pharmaceuticals LLC | $14.35 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.